Tianjin Medical University Second Hospital

This phase 2 trial is testing whether toripalimab, an immunotherapy drug, can prevent high-risk kidney cancer from coming back after surgery to remove the kidney. About 100 participants will receive the drug every three weeks for up to a year. Researchers will track how long they…